gilheydari
Posted - 1 week ago
$AVIR This is good question? Why?
gilheydari
Posted - 1 week ago
$AVIR
Larry_Klein
Posted - 1 week ago
$AVIR $VNDA MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏
lucky9150
Posted - 1 week ago
$AVIR , why filling for $ 500 millions stock offering? even though they have $ 500 millions cash on hand. Make no sense to me. Anyone?????
DonCorleone77
Posted - 2 weeks ago
$AVIR Atea Pharmaceuticals files $500M mixed securities shelf
FastTrack2Wealth
Posted - 2 weeks ago
🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $GNFT $AVIR $VNDA $ELDN
lucky9150
Posted - 2 weeks ago
$AVIR , looking 👍 great
lucky9150
Posted - 3 weeks ago
$AVIR , $ 5 after 15th November data release.
Chrissytina
Posted - 1 month ago
$AVIR What now 🤦🏼♀️
swingingtech
Posted - 1 month ago
$ZBH $AVIR $RDNT $TMDX
https://wallstreetwaves.com/zbh-prepares-for-q3-earnings-insights-and-predictions-for-investors/
ZenInvestorZR
Posted - 1 month ago
$AVIR The company's lead antiviral drug candidate, Bemnifosbuvir, is showing strong potential in late-stage trials, particularly in the treatment of COVID-19 and hepatitis C. Positive data from Phase 3 trials, particularly the SUNRISE-3 study for COVID-19, have sparked renewed investor interest. Furthermore, Atea has received Fast Track designation from the FDA for Bemnifosbuvir, which accelerates the drug's regulatory review, creating optimism about its potential market entry. In addition, Atea’s strategic collaborations, including ongoing clinical trials and presentations at major healthcare conferences, have bolstered confidence in the company’s future prospects, driving the recent stock price surge
Covid_Sucks
Posted - 1 month ago
$AVIR "During the nearly 3-year follow-up period, the risk of heart attack, stroke and death was more than two times higher among adults who had COVID-19, and nearly four times greater among adults hospitalized with COVID-19, compared with the group with no history of COVID-19 infection."
Covid_Sucks
Posted - 1 month ago
$AVIR Study released today with the AHA saying COVID-19 infection appeared to increase risk of heart attack & stroke up to 3 years later The AHA publication stated that "The elevated risk of heart attack, stroke and death linked to COVID-19 infection was found to be comparable to cardiovascular risk factors such as Type 2 diabetes, peripheral artery disease and cardiovascular disease" While our failed phase 3 couldn't demonstrate a decrease in 30 day hospitalization or death, if you looked at these more subtle long covid issues, such as heart attack or stroke within 3 years, my bet is that AT-527 will demonstrate a statistically significant improvement in outcomes. Covid-19 is not the flu. Still holding my position in AVIR Check out the press release, fresh out today! https://newsroom.heart.org/news/covid-19-infection-appeared-to-increase-risk-of-heart-attack-stroke-up-to-3-years-later
tradethehalt
Posted - 2 months ago
$AVIR the price is up 37.63% since we first alerted at 6:55am EDT.
neolithica
Posted - 2 months ago
$AVIR interesting.
tradethehalt
Posted - 2 months ago
$AVIR the price is up 34.05% since we first alerted at 6:55am EDT.
OpenOutcrier
Posted - 2 months ago
$AVIR (-1.9% pre) Atea Pharmaceuticals Inc. (AVIR) Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 Did Not Meet Primary Endpoin - SI https://ooc.bz/l/42319
MadHatterTrades74
Posted - 2 months ago
$AVIR Someone is betting that this drops below $2.5
ikkydiphoenix
Posted - 2 months ago
$AVIR
G101SPM
Posted - 2 months ago
$AVIR $3.37 bid. SELL on compromised SPM tag. DAC $3.34 (8.13.24)
LamBrad
Posted - 2 months ago
$AVIR Someone trying to prop this up - surprised it's still above $3
DARKP00L
Posted - 2 months ago
$AVIR Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
DonCorleone77
Posted - 2 months ago
$AVIR Atea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint Atea Pharmaceuticals announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. In SUNRISE-3, bemnifosbuvir was generally safe and well tolerated.
Baltic_Roots
Posted - 2 months ago
$AVIR -80% unfortunately 😕
MadHatterTrades74
Posted - 2 months ago
$AVIR Bad News
Stock_Titan
Posted - 2 months ago
$AVIR Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-provides-update-on-global-phase-3-sunrise-3-wo2vzfgc18vs.html
Stock_Titan
Posted - 08/28/24
$AVIR Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-announces-publication-of-additional-data-u1ezj1us83e2.html
The__Shane
Posted - 3 months ago
$AVIR It took me a little bit but I did eventually realize that i was talking to my self. Punk Ass Bitches! I think we're alone now There doesn't seem to be anyone around. Running just as fast as we can Holding on to one another's hand. Trying to get away into the night. And then you put your arms around me. And we tumble to the ground. And then you say... I think we're alone now Ha, feel free to have that stuck in your head or the rest of the day. XOXO's
The__Shane
Posted - 3 months ago
$AVIR I had an order in at $3.82 In after hours and they didn't pick it up. Was anyone able to buy? The numbers kept on shifting around but I don't think the volume even moved. Hummrnm.... It's on the NASDAQ
G101SPM
Posted - 3 months ago
$AVIR $3.34 ask. BUY/NEW LONG POSITION carries SPM 84.96 tag to $7.50 in midterm.